I'm still running on the warm glow hearing news that trial enrolment completion was sufficient at 120 instead of 150 because of the previous positive results.
Just my thoughts: FDA will hang off until BARDA completes trial (Sep 2025 from webcast) With competitors already feeling the pinch in the US and the anticipated positive results from a leading research facility, should be enough weight for approval, alot of white noise in between time, as per usual.
PNV Price at posting:
$2.30 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)